12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersDynatronics (NASDAQ:DYNT) stock rose 84.9% to $0.69 during Tuesday's pre-market session. The company's market cap stands at $3.3 million. BioRestorative Therapies (NASDAQ:BRTX) shares rose 23.4
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
Maxim Group Sticks to Their Buy Rating for Dermata Therapeutics (DRMA)
Dermata to Present at the Emerging Growth Conference on April 3, 2024
- Dermata to provide a corporate update followed by a live question and answer session -SAN DIEGO, CA / ACCESSWIRE / March 27, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the
Dermata Therapeutics FY23 EPS $(2.67) Vs $(13.92) YoY
Full Year 2023 Financial ResultsAs of December 31, 2023, the Company had $7.4 million in cash and cash equivalents, compared to $6.2 million as of December 31, 2022. The increase in cash and cash equi
Dermata Therapeutics: Unveiling Recent Financial Performance
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results
- Initiated enrollment of DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial in Q4 2023 -- Raised $9.1 million in gross proceeds from three financings completed in 2023 -- Rec
Dermata to Present at the Emerging Growth Conference on February 7, 2024
- Company to provide a corporate overview followed by a live question and answer session -SAN DIEGO, CA / ACCESSWIRE / February 1, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Derma
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersTivic Health Systems (NASDAQ:TIVC) stock rose 25.9% to $1.75 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.5 million. Bullfrog AI Hldgs (NASDAQ:BF
12 Health Care Stocks Moving In Friday's After-Market Session
GainersHeart Test Laboratories (NASDAQ:HSCS) stock moved upwards by 41.6% to $0.23 during Friday's after-market session. The market value of their outstanding shares is at $14.8 million. MyMD Pharmace
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected
US stocks look set to open lower in Friday's trading session as investors react to employment figures released earlier in the morning that were much stronger than expected. Total nonfarm payroll emplo
Dermata Stock Soars on Patent Issuance, Partnership Talks
Investors Await Jobs Data as US Futures Trend Lower in Friday's Premarket
US stock futures were trending lower in Friday's premarket session as investors await employment figures, as well as factory order data, and the Baker Hughes rig count scheduled later in the morning.
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersAinos (NASDAQ:AIMD) shares rose 150.3% to $4.33 during Friday's pre-market session. The company's market cap stands at $20.2 million. Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 6
Top Premarket Gainers
Dermata Therapeutics (DRMA) shares surged over 69% in Friday's premarket activity after saying it has been issued a new patent in Japan for its DMT410 program to treat hyperhidrosis. Safe and Green De
Stocks to Watch: Dermata Therapeutics, Applied Therapeutics, Fusion Pharmaceuticals
By Denny Jacob Dermata Therapeutics received a newly issued patent in Japan. Shares more than doubled in after-market trading. Applied Therapeutics said a trial of AT-001 failed to show a statistica
Dermata Therapeutics Shares Surge 120% on Patent Issued in Japan
By Denny Jacob Shares of Dermata Therapeutics more than doubled in post-market trading on Thursday following a newly issued patent in Japan. The stock rose 120% to $1.36. The shares have plunged 87%
Why Dermata Therapeutics Stock Took Off After-Hours
Dermata Therapeutics, Inc. (NASDAQ:DRMAW) shares are trading higher in Thursday's after-hours session after the company announced the issuance of a new patent in Japan for its DMT410 program for the
Dermata Expands Global Intellectual Patent Portfolio With Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis
- This is the Company's first patent issued for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -- The Company is currently discussing partnership opportunities to advance
Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
- About 550 patients will be treated once weekly for 12 weeks -- STAR-1 topline results expected in first quarter of 2025 -- Acne affects about 50 million patients in the U.S. -SAN DIEGO, CA / ACCESSWIRE / December 20,
No Data